AR034355A1 - Nueva composicion farmaceutica - Google Patents

Nueva composicion farmaceutica

Info

Publication number
AR034355A1
AR034355A1 ARP020102074A ARP020102074A AR034355A1 AR 034355 A1 AR034355 A1 AR 034355A1 AR P020102074 A ARP020102074 A AR P020102074A AR P020102074 A ARP020102074 A AR P020102074A AR 034355 A1 AR034355 A1 AR 034355A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
new pharmaceutical
acid ester
ester
sucrose
Prior art date
Application number
ARP020102074A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR034355A1 publication Critical patent/AR034355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a una composición farmacéutica que comprende un inhibidor de lipasas, preferiblemente orlistat, con un punto de fusión >= 37°C, un éster de ácido graso de sacarosa en donde el éster de ácido de sacarosa es un mono-, di-, tri- o tetra-éster, y opcionalmente uno o más excipientes farmacéuticamente aceptables.
ARP020102074A 2001-06-06 2002-06-04 Nueva composicion farmaceutica AR034355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06

Publications (1)

Publication Number Publication Date
AR034355A1 true AR034355A1 (es) 2004-02-18

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102074A AR034355A1 (es) 2001-06-06 2002-06-04 Nueva composicion farmaceutica

Country Status (39)

Country Link
US (4) US20030027786A1 (es)
EP (1) EP1399152B1 (es)
JP (2) JP4261337B2 (es)
KR (1) KR100753729B1 (es)
CN (1) CN1514725B (es)
AR (1) AR034355A1 (es)
AT (1) ATE356622T1 (es)
AU (1) AU2002257817B2 (es)
BG (1) BG66346B1 (es)
BR (1) BRPI0210266B1 (es)
CA (1) CA2448030C (es)
CO (1) CO5540293A2 (es)
CY (1) CY1107641T1 (es)
CZ (1) CZ299948B6 (es)
DE (1) DE60218845T2 (es)
DK (1) DK1399152T3 (es)
EC (1) ECSP034871A (es)
ES (1) ES2282415T3 (es)
GT (1) GT200200106A (es)
HR (1) HRP20030983B1 (es)
HU (1) HU230405B1 (es)
IL (2) IL158908A0 (es)
JO (1) JO2455B1 (es)
MA (1) MA27031A1 (es)
ME (1) ME00579A (es)
MX (1) MXPA03011191A (es)
MY (1) MY161871A (es)
NO (1) NO328006B1 (es)
NZ (1) NZ529630A (es)
PA (1) PA8546701A1 (es)
PE (1) PE20030230A1 (es)
PL (1) PL215266B1 (es)
PT (1) PT1399152E (es)
RS (1) RS50713B (es)
RU (1) RU2271808C2 (es)
SI (1) SI1399152T1 (es)
SK (1) SK287602B6 (es)
WO (1) WO2002098412A1 (es)
ZA (1) ZA200309007B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
EP3364956A4 (en) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. ANALOG OF CELASTROL
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148917A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
EP0271963B1 (en) * 1986-12-19 1993-07-21 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
BR9912980B1 (pt) * 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
AU1031500A (en) 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
CA2358921A1 (en) 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
AU2001281846B2 (en) * 2000-06-27 2006-04-27 Cheplapharm Arzneimittel Gmbh Method for preparing a composition
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
HUP0401208A3 (en) 2008-04-28
HRP20030983B1 (hr) 2011-10-31
EP1399152A1 (en) 2004-03-24
ATE356622T1 (de) 2007-04-15
PT1399152E (pt) 2007-06-05
BG108421A (en) 2005-02-28
JO2455B1 (en) 2008-10-09
HK1067312A1 (zh) 2005-04-08
CA2448030A1 (en) 2002-12-12
JP2009108076A (ja) 2009-05-21
CZ299948B6 (cs) 2009-01-07
RS96003A (sr) 2006-10-27
JP4261337B2 (ja) 2009-04-30
MXPA03011191A (es) 2004-02-26
SK16092003A3 (sk) 2004-05-04
IL158908A (en) 2008-08-07
ZA200309007B (en) 2005-04-26
US20050101562A1 (en) 2005-05-12
AU2002257817B2 (en) 2005-08-18
NO328006B1 (no) 2009-11-09
US8343543B2 (en) 2013-01-01
ME00579B (me) 2011-12-20
RU2003136728A (ru) 2005-05-20
ME00579A (en) 2011-12-20
MA27031A1 (fr) 2004-12-20
HRP20030983A2 (en) 2005-08-31
NZ529630A (en) 2006-05-26
BR0210266A (pt) 2004-07-20
NO20035318D0 (no) 2003-11-28
DK1399152T3 (da) 2007-06-18
CN1514725A (zh) 2004-07-21
RS50713B (sr) 2010-06-30
CA2448030C (en) 2009-11-24
PA8546701A1 (es) 2003-01-24
DE60218845T2 (de) 2008-01-03
BRPI0210266B1 (pt) 2016-01-26
MY161871A (en) 2017-05-15
HUP0401208A2 (hu) 2004-11-29
CO5540293A2 (es) 2005-07-29
KR20040010689A (ko) 2004-01-31
PL366890A1 (en) 2005-02-07
JP2004532271A (ja) 2004-10-21
HU230405B1 (hu) 2016-04-28
KR100753729B1 (ko) 2007-08-30
GT200200106A (es) 2003-02-11
WO2002098412A1 (en) 2002-12-12
IL158908A0 (en) 2004-05-12
US20130079391A1 (en) 2013-03-28
US8039508B2 (en) 2011-10-18
RU2271808C2 (ru) 2006-03-20
US20030027786A1 (en) 2003-02-06
CZ20033525A3 (cs) 2004-04-14
DE60218845D1 (de) 2007-04-26
BG66346B1 (bg) 2013-08-30
US20110301231A1 (en) 2011-12-08
PE20030230A1 (es) 2003-03-17
PL215266B1 (pl) 2013-11-29
SK287602B6 (sk) 2011-03-04
EP1399152B1 (en) 2007-03-14
ECSP034871A (es) 2004-01-28
ES2282415T3 (es) 2007-10-16
CN1514725B (zh) 2010-04-21
CY1107641T1 (el) 2013-04-18
SI1399152T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
ECSP034871A (es) Composicion farmaceutica que comprende un inhibidor de lipasas y un ester de acido graso de sacarosa
NO20034920D0 (no) Styrking av terapeutiske virkninger av fettsyrer
BR0017161A (pt) Dispositivo de iluminação, e, pelìcula óptica
AU2003201693A1 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
BR0313876B1 (pt) uso de uma mistura, e, composições de combustível e de solvente
ATE374602T1 (de) Orale kapselformulierung mit verbesserter physikalischer stabilität
BR0112584A (pt) ésteres oxigenados de ácidos benzidroxâmicos de 4-iodofenilamino
NZ515016A (en) HIV protease inhibitor composition
UY26338A1 (es) Formulaciones dispersables conteniendo inhibidores de la lipasa
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
UY27321A1 (es) Nueva composición farmacéutica
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
PE20050629A1 (es) PROFARMACO DE SULFONA DEL ACIDO 6-ß-HIDROXIMETILPENICILANICO COMO INHIBIDOR DE BETA-LACTAMASA
DK0775692T3 (da) Guanidinomethylcyclohexancarboxylsyreesterderivater
ECSP993142A (es) Composicion farmaceutica
ECSP003653A (es) Formulaciones solidas de lipido
HN1996000075A (es) Nueva variante cristalina del cdch procedimientos para su produccion y preparados farmaceuticos que lo contienen.
ECSP003349A (es) Derivados de mevinolina
FR2843019B1 (fr) Composition gelifiee par un melange d'esters de dextrine
ECSP993102A (es) Composiciones farmaceuticas
ES2187962T3 (es) Derivados estrogenicos de la 19-norandrost-17-ona con un anillo aromatico b.
ECSP993090A (es) Composicion farmaceutica de proteinas erizo y su uso
DOP2001000214A (es) Esteres oxigenados de acidos 4-yodo benzhidroxamicos (oxigenated esters of 4-yodo phenylamino benzhydroxamic acids
IT1320100B1 (it) Formulazioni farmaceutiche a rilascio controllato di levodopa ecarbidopa.

Legal Events

Date Code Title Description
FC Refusal